Brian Skorney predicts Lilly's Lp(a) CVOT data may read out in 2029.
“You know, the Lilly data may be 2029, but it's kind of hard to look through this data and have a lot of confidence that Lp reductions pharmacologically are gonna make a material impact in cardiovascular outcomes.”
→ Read the source episode
Our resolution criterion
disputableLilly publicly announces results from their Lp(a) cardiovascular outcomes trial in a press release or scientific presentation
More from Biotech Hangout
Tarsus Pharmaceuticals' Alkias phase three Northstar study for gilderretinol will report data in H2 2029.
Ten X will meet with EMA to explore enriched patient populations for HFpEF drug following failed phase three.
Eric Schmidt predicts the HARMONY three study for evanesquimab will read out positively in 6-9 months.
Paul Matisse reports Biohaven's KV7 epilepsy drug is on partial clinical hold with phase 3 data coming soon.
Daphne Zohar predicts Heidi Overton's FDA commissioner confirmation hearings will occur after the Senate summer recess.
Belight Bio's tennleribans will receive FDA approval decision by February 12, 2027 for Stargardt disease.
Summaries are ours; the quote is a verbatim transcript excerpt. Our resolution criteria are editorial and disputable. How this works.